Frederic de Blay Alyatec allergen exposure chamber unit allergen clinical trials allergy Regeneron Pharmaceuticals

 

 

 

 

 

 

 

 

The results of a clinical study carried out by ALYATEC for the American pharmaceutical company Regeneron Pharmaceuticals were presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology (26th February to 1st March 2021).

On this occasion, Prof. de Blay, principal investigator of the study and medical expert of ALYATEC, spoke to Medscape. In this interview, he reviews the progress of the clinical trial and shares his impressions about these very promising results.

 

The article can be read here: Novel Agent Shows Promise Against Cat Allergy

 

 

Alyatec de Blay Regeneron